Thanks for the article APHA looks like the way to go volatile for sure
8:57am 2/16/2021 UPDATE: To profit from planned merger of Tilray and Aphria, buy Aphria, says this analyst
Mentioned: APHA TLRY
Investors seeking to profit from the merger of Canadian cannabis companies Tilray Inc. and Aphria Inc. are best to do so by buying shares of Aphria, which are trading at a 51% discount over the merger conversion price, Cantor Fitzgerald analyst Pablo Zuanic said Tuesday.
Zuanic reiterated his overweight rating on Aphria stock (APHA.T) and raised his 12-month price target to C$32.50 ($25.71) from C$26.00. He also stuck with his neutral rating on Tilray (TLRY), while raising his price target to $30.25 from $24.20.
"The recent significant bout of volatility in Canadian cannabis stocks may be another deterrent for investors looking at this subsector (aside of mixed fundamentals and valuation)," Zuanic wrote in a note to clients. "But with US MSOs (multi-state operators) landlocked, we continue to think the larger better managed Canadian LPs deserve a premium for global growth potential."
Read now:Aurora Cannabis stock slides as analysts weigh in on weak quarterly earnings and one downgrades to sell
The planned merger continues to make strategic sense and the combined company could eventually look attractive to consumer packaged goods companies, and could attract a U.S. suitor before the end of cannabis prohibition, he wrote.
Read: Cannabis stocks nosedive as rally driven by hopes for U.S. legal reforms comes to a screeching halt (https://www.marketwatch.com/story/cannabis-stocks-nosedive-as-rally-driven-by-hopes-for-u-s-reforms-comes-to-a-screeching-halt-11613069414
The combined company will have close to two times the size of Canopy Growth Corp.'s (WEED.T) share of the Canadian recreational cannabis market, and offers 51% upside for Aphria shares and about 4% for Tilray, he wrote.
Under the terms of the deal, (https://www.marketwatch.com/story/tilray-stock-rockets-after-reverse-merger-deal-with-aphria-to-create-largest-global-cannabis-company-11608128018)Aphria
shareholders will received 0.8381 Tilray shares for each share owned.
"Thus, using TLRY's closing price of US$29 on 2/12, this would mean APHAshares would be worth C$31," said Zuanic. Cantor is not expecting the deal terms to be renegotiated, but rather views the gap as a result of recent volatility in Canadian cannabis stocks with Tilray the most liquid given its Nasdaq listing.
Read now: Cannabis stocks rally after Chuck Schumer leads drive for reforms that may end federal prohibition (https://www.marketwatch.com/story/cannabis-stocks-rally-after-chuck-schumer-leads-drive-for-reforms-that-will-end-federal-prohibition-11612292635?mod=cannabis-watch
"We would put the likelihood of other bidders emerging at less than5% (not for tiny TLRY on its own) and renegotiated terms at less than 20% (we do not think TLRY has much bargaining power)," said the note.
Aphria shares were up 8.4% premarket and have gained 293% in the last 12 months. Tilray's stock was up 6.4% and has gained 67% in the last 12 months.
The Cannabis ETF (THCX), up 3.4% premarket, has gained 94% in the same time frame, while the S&P 500 has gained 16%.
For more of MarketWatch's cannabis coverage, see: Cannabis Watch (https://www.marketwatch.com/column/cannabis-watch?mod=breadcrumb
-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
February 16, 2021 08:57 ET (13:57 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.